Vaxcyte reports Q4 2022 net loss of $78.1M; cash $957.9M; VAX-24 infant IND cleared

Vaxcyte, Inc.

2022-FY EPS reported -$3.44

Net loss of $78.1M for Q4 2022 and $223.5M for full year 2022; R&D expenses $51.6M and $169.5M respectively.
Cash, cash equivalents and investments $957.9M as of Dec 31, 2022, up from $273.1M a year ago.
FDA cleared VAX-24 infant IND; Phase 2 infant study to start Q2 2023; Breakthrough Therapy designation for adults.
Positive Phase 1/2 data for VAX-24 in adults 18-64; Phase 2 study in adults 65+ enrollment completed; topline data expected Q2 2023.
Raised ~$805M in gross proceeds from two follow-on equity offerings in 2022; VAX-31 adult IND expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vaxcyte, Inc. reported financial results for the quarter and full year ended December 31, 2022.

Period: the quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 27, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-004639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.